Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration
- PMID: 15656698
- DOI: 10.2165/00003088-200544020-00005
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration
Abstract
Background: The minimum inhibitory concentration (MIC) is the in vitro reference value to describe the activity of an antibacterial against micro-organisms. It does not represent the dynamic effect of the antimicrobial at any point in time, but rather the total antimicrobial effect over the incubation period at a fixed concentration.
Objective: To explore the concentration-effect relationship of antimicrobial concentrations against micro-organisms in relation to the MIC.
Methods: Time-kill curves were generated for ceftazidime, meropenem and tobramycin against Pseudomonas aeruginosa. The Hill equation with variable slope was fit to the time-kill data, and mathematical models of growth and kill were explored with reference to the MIC.
Results: With declining concentrations, bacterial killing will decrease until a specific threshold concentration is reached. This concentration, at which bacteria are neither killed nor able to grow, is named the stationary concentration (SC) and is not equal to the MIC. Pharmacokinetic/pharmacodynamic simulations over a range of kill rates, growth rates and slope factors showed that for beta-lactam antibacterials, the SC is close to the MIC value, which may explain why concentrations in vivo need to be above the MIC, while regrowth of bacteria occurs when concentrations decline below the MIC. For concentration-dependent antibacterials, such as aminoglycosides and quinolones, the SC is shown to be markedly different from the MIC and, in general, is much lower.
Conclusion: The MIC is not a good pharmacodynamic parameter to characterise the concentration effect relationship of a given antimicrobial. For 'concentration independent' antimicrobials the SC is likely to be close to the MIC, but may be much lower for 'concentration dependent' antimicrobials, and may explain sub-MIC effects.
Comment in
-
Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations.Clin Pharmacokinet. 2005;44(7):767-8. doi: 10.2165/00003088-200544070-00007. Clin Pharmacokinet. 2005. PMID: 15966758 No abstract available.
Similar articles
-
Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.Int J Antimicrob Agents. 2015 Feb;45(2):151-60. doi: 10.1016/j.ijantimicag.2014.09.017. Epub 2014 Nov 1. Int J Antimicrob Agents. 2015. PMID: 25465523
-
Soup with or without meatballs: Impact of nutritional factors on the MIC, kill-rates and growth-rates.Eur J Pharm Sci. 2018 Dec 1;125:23-27. doi: 10.1016/j.ejps.2018.09.008. Epub 2018 Sep 12. Eur J Pharm Sci. 2018. PMID: 30218696
-
Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.Antimicrob Agents Chemother. 2008 Nov;52(11):3987-93. doi: 10.1128/AAC.01468-07. Epub 2008 Aug 25. Antimicrob Agents Chemother. 2008. PMID: 18725438 Free PMC article.
-
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.Clin Pharmacokinet. 1995 Feb;28(2):143-60. doi: 10.2165/00003088-199528020-00005. Clin Pharmacokinet. 1995. PMID: 7736689 Review.
-
The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.Dan Med Bull. 2000 Nov;47(5):313-27. Dan Med Bull. 2000. PMID: 11155659 Review.
Cited by
-
Antibiotics in anesthesia and critical care.Ann Transl Med. 2024 Feb 1;12(1):6. doi: 10.21037/atm-22-5585. Epub 2023 Dec 13. Ann Transl Med. 2024. PMID: 38304898 Free PMC article. Review.
-
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.J Pharmacokinet Pharmacodyn. 2007 Dec;34(6):727-51. doi: 10.1007/s10928-007-9069-x. Epub 2007 Sep 29. J Pharmacokinet Pharmacodyn. 2007. PMID: 17906920 Review.
-
Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.Clin Pharmacokinet. 2019 May;58(5):545-564. doi: 10.1007/s40262-018-0705-y. Clin Pharmacokinet. 2019. PMID: 30097887 Review.
-
The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions.Antibiotics (Basel). 2025 May 27;14(6):545. doi: 10.3390/antibiotics14060545. Antibiotics (Basel). 2025. PMID: 40558135 Free PMC article. Review.
-
Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design.Antimicrob Agents Chemother. 2013 May;57(5):2343-51. doi: 10.1128/AAC.00092-13. Epub 2013 Mar 11. Antimicrob Agents Chemother. 2013. PMID: 23478962 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical